A drug called interferon helps in 40 percent of cases, but the benefits are short-lived.
Two studies published in the current New England Journal of Medicine offer new hope.
According to this week's New England Journal of Medicine, six months after treatment, patients who received the two-drug combination were more likely to be free of hepatitis C than they would be if they accepted the traditional drug treatment of interferon.
Fisher's Specialized Pharmacy Services, a drug store in Pittsburgh, began selling its version of the drugs.
Hepatitis C is spread by blood and affects an estimated 3.9 million people in the United States.
Folkman was making the first public comments to cancer specialists about the drug's effectiveness.
China has put onto the market five genetic engineering drugs, and another dozen such drugs are under research.
It suppresses blood levels of the virus far better than interferon alone.
Most patients treated with interferon relapse.
That therapy eliminates the disease in only 10 percent to 20 percent of patients.
Only one-third of patients who gave themselves weekly thigh injections of the drug developed MS compared with half the patients who injected a harmless substance.
The vast majority of people with chronic hepatitis C carry the virus apparently with few ill effects.
Hoping to prevent further liver damage, her doctor recommended drug treatment to try to rid her system of the virus.
